American Gastroenterological Association Institute Guideline on 1 the Prevention and Treatment of Hepatitis B Reactivation During 2 Immunosuppressive Drug Therapy
نویسندگان
چکیده
4 K. Rajender Reddy, Kimberly L. Beavers, Sarah P. Hammond, Joseph K. Lim, Yngve T. 5 Falck-Ytter, 5 and the Clinical Guidelines Committee of the American Gastroenterological 6 Association 7 8 1 Division of Gastroenterology and Hepatology University of Pennsylvania; 2 Division of 9 Gastroenterology and Hepatology, Medical University of South Carolina; 3 University of Michigan, 10 Ann Arbor, MI; 4 Division of Gastroenterology and Hepatology, Yale University School of 11 Medicine; 5 Division of Gastroenterology and Hepatology, Department of Medicine, Case and VA 12 Medical Center, Case Western Reserve University, Cleveland, Ohio 13 14 Acknowledgements: Clinical Guidelines Committee included: Steven L. Flamm, Northwestern 15 Feinberg School of Medicine, Chicago, IL; Lauren Gerson, California Pacific Medical Center, San 16 Francisco, CA; Ikuo Hirano, Northwestern University School of Medicine, Chicago, Il; Joseph K. 17 Lim, Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut; Geoffrey 18 Nguyen, Mount Sinai Hospital, New York, NY; Joel H. Rubenstein, Veterans Affairs Center for 19 Clinical Management Research, Ann Arbor, Michigan and Division of Gastroenterology, 20 University of Michigan Medical School, Ann Arbor, Michigan; Siddharth Singh, Division of 21 Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; Neil Stollman, University of 22 California San Francisco, Northern California Gastroenterology Consultants, San Francisco, CA; 23 Santhi S. Vege, Pancreas Group, Division of Gastroenterology and Hepatology, Mayo Clinic, 24 Rochester, MN; David S. Weinberg, Fox Chase Cancer Center, Philadelphia, PA; Yu-Xiao Yang, 25 Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, 26 Philadelphia, Pennsylvania 27 28
منابع مشابه
Patients with Coexistence of Circulating Hepatitis B Surface Antigen and Its Antibody May Have a Strong Predisposition to Virus Reactivation During Immunosuppressive Therapy: A Hypothesis
Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients who undergo immunosuppressive drug therapy. Although the recommendation of antiviral prophylaxis made by the American Gastroenterological Association in 2015 focuses on the risk stratification of different immunosuppressive drugs, risk factors for HBV reactivation are also worth identifying in clinical practice. ...
متن کاملImmunosuppression in Patients with Chronic Hepatitis B
After hepatitis B virus (HBV) infection, HBV DNA persists in minute amounts in hepatocyte nuclei even in individuals with "resolved" infection. Viral replication and development of liver disease depend on the balance between viral mechanisms promoting persistence and host immune control. Patients with active or inactive disease or resolved HBV infection are at risk for reactivation with immunos...
متن کاملHepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents.
Hepatitis due to reactivation of hepatitis B virus (HBV) has been reported in patients treated with direct-acting antiviral (DAA) agents for chronic hepatitis C virus infection. We performed an observational study to determine the incidence of and factors associated with hepatitis in 327 patients receiving pan-oral DAA agents for HCV infections in areas endemic for HBV in China. Ten patients we...
متن کاملOccult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals.
متن کامل
Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Viral reactivation in hepatitis B surface antigen (HBsAg) carriers undergoing immunosuppressive therapy is well documented. To evaluate the role of lamivudine prophylaxis in Hepatitis B virus (HBV) carriers treated with immunosuppression for nonhepatic disorders, we reviewed our experience between 1997 and 2000 at Hadassah University Hospital (Jerusalem, Israel). Controls were patients who were...
متن کامل